TICKERNOMICS Sign up
Last Update: 2023-10-20 13:12:38
Radius Heal ( RDUS ) https://radiuspharm.com
25.02USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
18.43%
RDUS
155.65%
SPY
32.62%
RDUS
116.85%
SPY
77.59%
RDUS
65.11%
SPY
247.92%
RDUS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
479.69
748.02
0.17
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-6.99
2.15
-1.75
-7.73
7.44
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-13.47
90.43
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
-0.58
-40.42
-40.96
-1.60
Other Earnings and Cash Flow Stats:
Radius Heal ( RDUS ) Net Income TTM ($MM) is -67.16
Radius Heal ( RDUS ) Operating Income TTM ($MM) is -48.77
Radius Heal ( RDUS ) Owners' Earnings Annual ($MM) is -27.92
Radius Heal ( RDUS ) Current Price to Owners' Earnings ratio is -17.51
Radius Heal ( RDUS ) EBITDA TTM ($MM) is -47.47
Radius Heal ( RDUS ) EBITDA Margin is 0.00%
Capital Allocation:
Radius Heal ( RDUS ) has paid 0.75 dividends per share and bought back 0.0 million shares in the past 12 months
Radius Heal ( RDUS ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Radius Heal ( RDUS ) Interest-bearing Debt ($MM) as of last quarter is 340
Radius Heal ( RDUS ) Annual Working Capital Investments ($MM) are -17
Radius Heal ( RDUS ) Book Value ($MM) as of last quarter is -274
Radius Heal ( RDUS ) Debt/Capital as of last quarter is -125%
Other Balance Sheet Stats:
Radius Heal ( RDUS ) has 72 million in cash on hand as of last quarter
Radius Heal ( RDUS ) has 87 million of liabilities due within 12 months, and long term debt 341 as of last quarter
Radius Heal ( RDUS ) has 47 common shares outstanding as of last quarter
Radius Heal ( RDUS ) has 294 million USD of preferred stock value
Academic Scores:
Radius Heal ( RDUS ) Altman Z-Score is 0.00 as of last quarter
Radius Heal ( RDUS ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Radius Heal ( RDUS ) largest shareholder is Geode Capital Management, LLC owning 532082 shares at 13.31 ($MM) value
Michael R Henderson(an insider) Sold 1691 shares of Radius Heal ( RDUS ) for the amount of $46401.04 on 2023-05-04
0.53% of Radius Heal ( RDUS ) is held by insiders, and 106.75% is held by institutions
Radius Heal ( RDUS ) went public on 2014-06-06
Other Radius Heal ( RDUS ) financial metrics:
FCF:-2.53
Unlevered Free Cash Flow:2.72
EPS:-1.07
Operating Margin:-13.47
Gross Profit Margin:90.43
Div. Payout Ratio%:-52.01
Div. Growth YoY%:0.00
Equity Return%:18.63
Beta:-1.60
Buffet's Owners Earnings:-27.92
Price to Owner's Earnings:-17.51
About Radius Heal ( RDUS ) :
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.